KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.
By W. Roock, H. Piessevaux, J. Schutter, M. Janssens, G. Hertogh, N. Personeni, B. Biesmans, J. Laethem, M. Peeters, Y. Humblet and 2 more. Annals of Oncology, 2008
891 citations recorded by the source corpus.
Subfields: Molecular Biology, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/b4509866bc94776dfbf3256a4af453263b188c23
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Oncology
Citations in the corpus
- American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. (2009, methodology): “The review of the evidence on which this PCO is based consists primarily of the rigorous systematic review of the literature conducted by the Blue Cross and Blue Shield Association (BCBSA) Technology Evaluation Center (TEC).(1-10) Details of the BCBSA TEC assessment can be found in the full TEC repo”
- Tumour heterogeneity in the clinic (2013, background): “An example is the inclusion of different tumour types that harbour PIK3CA mutations or amplifications into a basket trial that evaluates a PI(3)K α-isoform specific inhibitor (NCT01219699).”
- Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. (2010, methodology): “Second, anecdotal reports indicate that a minority of patients ( 10%) with KRAS-mutated tumors can respond to anti-EGFR therapy(6-9) and that about 15% have longterm disease stabilization.(10) In these patients’ tumors, codon 13 mutations were overrepresented compared with the overall KRAS-mutated t”